Why Medication Changes Are Often Slow and Cautious

Why this matters

When treatment isn’t working as hoped, waiting weeks or months for an adjustment can feel frustrating. Understanding the clinical reasoning behind the pace makes it easier to trust the process and to recognise the situations where faster action is genuinely warranted.

Why changes are slow

• One variable at a time. Changing multiple things simultaneously makes it impossible to know what worked or caused problems. Sequential adjustments produce clearer cause-and-effect information, which informs every subsequent treatment decision
• Assessing true response takes time. Medications take weeks to months to reach full effect, and changing treatment before that window closes risks abandoning something that would have worked
• Starting low and increasing gradually. High starting doses often cause side effects that lead to treatment being stopped entirely. Gradual escalation allows tolerance to develop and improves the chance of reaching a therapeutic dose
• Safety monitoring between changes. Some medications require blood counts, liver, or kidney function to be checked before doses are increased. Skipping this risks toxicity going undetected
• Drug interactions and complexity. When multiple medications are involved, sequential adjustments are safer than changing several things at once

When slow changes are appropriate

• Stable disease with minor symptoms. Cautious dose optimisation avoids destabilising what’s already largely controlled
• Starting a new treatment. Established dose escalation protocols are slower but evidence-based
• Complex comorbidities. Multiple conditions, organ impairment, or extensive medication lists all require extra caution
• Older patients. Drug metabolism differs with age, and side effect risk is higher

When speed is justified

Slow isn’t always appropriate. Rapid escalation is warranted when the disease is severe and causing organ damage or significant functional impairment. It’s also justified when treatment has clearly failed after an adequate trial, when side effects are intolerable, or when there’s a high risk of irreversible damage where urgency outweighs the case for caution.

What you could do

• If the pace of change feels too slow, ask directly: "My symptoms are significantly affecting my quality of life. Can we discuss whether faster escalation is safe?" or "What evidence would convince you that current treatment has failed?"
• Communicate functional impact clearly. If symptoms are making daily life very difficult, escalation may be justified and that case is worth making
• Balance patience with advocacy. Adequate trials are needed, but prolonged delay while suffering is unacceptable
• Track medication timing, doses, and symptom changes so that the clinical team has clear evidence to work with at the next review

This article is for general information purposes only and doesn’t constitute legal, financial or benefits advice. For advice specific to your situation, please speak to a qualified professional or contact an organisation such as Citizens Advice, who may be able to assist you further.

References:

‘Comparing myelosuppression frequency in Indian inflammatory bowel disease patients: a randomized trial of full dose versus gradual escalation of thiopurines’ (2024) https://www.cureus.com/articles/210109-comparing-myelosuppression-frequency-in-indian-inflammatory-bowel-disease-patients-a-randomized-trial-of-full-dose-versus-gradual-escalation-of-thiopurines#!/

‘EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update’ (2020) https://doi.org/10.1136/annrheumdis-2019-216655

‘Rheumatoid arthritis in adults: management (NICE guideline NG100)’ (2022) https://www.nice.org.uk/guidance/ng100